Market Closed -
Nasdaq
04:30:00 2024-05-03 pm EDT
|
5-day change
|
1st Jan Change
|
137
USD
|
+0.55%
|
|
+0.63%
|
+16.88%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
8,503
|
14,728
|
16,414
|
7,777
|
6,194
|
7,249
|
-
|
-
|
Enterprise Value (EV)
1 |
7,815
|
14,087
|
15,668
|
7,777
|
6,194
|
5,248
|
5,509
|
5,343
|
P/E ratio
|
46.1
x
|
64.6
x
|
74.7
x
|
56.9
x
|
77.6
x
|
68.9
x
|
47.3
x
|
39.7
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
9.07
x
|
12.9
x
|
13.2
x
|
3.82
x
|
3.02
x
|
3.45
x
|
3.25
x
|
3.06
x
|
EV / Revenue
|
8.33
x
|
12.3
x
|
12.6
x
|
3.82
x
|
3.02
x
|
2.5
x
|
2.47
x
|
2.26
x
|
EV / EBITDA
|
31.5
x
|
48.1
x
|
47.4
x
|
15.6
x
|
15.1
x
|
12.8
x
|
12
x
|
10.7
x
|
EV / FCF
|
51
x
|
102
x
|
65.5
x
|
-389
x
|
124
x
|
29.8
x
|
15.9
x
|
13.6
x
|
FCF Yield
|
1.96%
|
0.98%
|
1.53%
|
-0.26%
|
0.81%
|
3.36%
|
6.29%
|
7.38%
|
Price to Book
|
7.29
x
|
10.5
x
|
10.6
x
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
53,611
|
55,055
|
55,222
|
52,565
|
52,841
|
52,913
|
-
|
-
|
Reference price
2 |
158.6
|
267.5
|
297.2
|
148.0
|
117.2
|
137.0
|
137.0
|
137.0
|
Announcement Date
|
2/19/20
|
2/23/21
|
2/15/22
|
2/28/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
937.8
|
1,144
|
1,239
|
2,036
|
2,048
|
2,102
|
2,229
|
2,369
|
EBITDA
1 |
248.2
|
292.9
|
330.5
|
498.3
|
411.3
|
409.8
|
458.1
|
498.8
|
EBIT
1 |
224.7
|
263.6
|
294.8
|
362.2
|
313
|
315.7
|
351.1
|
394.4
|
Operating Margin
|
23.96%
|
23.05%
|
23.79%
|
17.79%
|
15.28%
|
15.01%
|
15.76%
|
16.65%
|
Earnings before Tax (EBT)
1 |
234.2
|
263.7
|
274.4
|
193.4
|
88.1
|
156.9
|
214.4
|
255.4
|
Net income
1 |
196.2
|
240.3
|
229.6
|
143.5
|
81.5
|
109.1
|
162.7
|
196.7
|
Net margin
|
20.92%
|
21.01%
|
18.53%
|
7.05%
|
3.98%
|
5.19%
|
7.3%
|
8.3%
|
EPS
2 |
3.440
|
4.140
|
3.980
|
2.600
|
1.510
|
1.988
|
2.897
|
3.450
|
Free Cash Flow
1 |
153.3
|
138.4
|
239.3
|
-20
|
50.1
|
176.1
|
346.6
|
394.3
|
FCF margin
|
16.34%
|
12.1%
|
19.31%
|
-0.98%
|
2.45%
|
8.38%
|
15.55%
|
16.65%
|
FCF Conversion (EBITDA)
|
61.76%
|
47.25%
|
72.4%
|
-
|
12.18%
|
42.97%
|
75.67%
|
79.05%
|
FCF Conversion (Net income)
|
78.11%
|
57.6%
|
104.18%
|
-
|
61.47%
|
161.41%
|
213.07%
|
200.44%
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
2/19/20
|
2/23/21
|
2/15/22
|
2/28/23
|
2/27/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
2025 Q1
|
---|
Net sales
1 |
307.4
|
327.6
|
304.2
|
565.3
|
549.3
|
617
|
565
|
455.3
|
478.9
|
548.9
|
487.7
|
502.7
|
508.9
|
603.1
|
518.4
|
EBITDA
1 |
79.9
|
93.41
|
78.96
|
176.8
|
58
|
183.9
|
101.6
|
83.8
|
81.4
|
114.2
|
88.13
|
95.73
|
97.5
|
126.4
|
96.46
|
EBIT
1 |
70.77
|
84.24
|
69.82
|
106
|
81.3
|
104.4
|
75.5
|
58.6
|
56.9
|
91.7
|
65
|
72.12
|
74.16
|
102
|
77.25
|
Operating Margin
|
23.02%
|
25.71%
|
22.95%
|
18.75%
|
14.8%
|
16.92%
|
13.36%
|
12.87%
|
11.88%
|
16.71%
|
13.33%
|
14.35%
|
14.57%
|
16.91%
|
14.9%
|
Earnings before Tax (EBT)
1 |
67.53
|
76.7
|
59.14
|
26.6
|
52
|
55.7
|
26.2
|
24.8
|
14
|
23.2
|
25.87
|
31.67
|
32.76
|
66.63
|
38.6
|
Net income
1 |
57.77
|
68.26
|
46.6
|
18.1
|
37.9
|
41.1
|
21.3
|
15.7
|
10.6
|
34
|
18.48
|
21.94
|
24.26
|
44.23
|
34.46
|
Net margin
|
18.79%
|
20.84%
|
15.32%
|
3.2%
|
6.9%
|
6.66%
|
3.77%
|
3.45%
|
2.21%
|
6.19%
|
3.79%
|
4.36%
|
4.77%
|
7.33%
|
6.65%
|
EPS
2 |
1.000
|
1.180
|
0.8100
|
0.3300
|
0.7000
|
0.7600
|
0.3900
|
0.2900
|
0.2000
|
0.6300
|
0.3414
|
0.3983
|
0.4400
|
0.7950
|
0.6133
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
10/26/21
|
2/15/22
|
5/3/22
|
8/9/22
|
11/8/22
|
2/28/23
|
5/9/23
|
8/8/23
|
11/7/23
|
2/27/24
|
-
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
688
|
641
|
745
|
-
|
-
|
2,001
|
1,740
|
1,906
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
153
|
138
|
239
|
-20
|
50.1
|
176
|
347
|
394
|
ROE (net income / shareholders' equity)
|
18.4%
|
18.7%
|
15.5%
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
15.4%
|
15.5%
|
12.8%
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
1,276
|
1,554
|
1,800
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
21.80
|
25.50
|
28.00
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
3.880
|
-
|
4.590
|
0.5300
|
-
|
-
|
-
|
-
|
Capex
1 |
68.4
|
72.5
|
25.5
|
49.5
|
-
|
51.5
|
72.1
|
75.1
|
Capex / Sales
|
7.29%
|
6.34%
|
2.06%
|
2.43%
|
-
|
2.45%
|
3.23%
|
3.17%
|
Announcement Date
|
2/19/20
|
2/23/21
|
2/15/22
|
2/28/23
|
2/27/24
|
-
|
-
|
-
|
Average target price
150
USD Spread / Average Target +9.51% Consensus |
1st Jan change
|
Capi.
|
---|
| +16.88% | 7.25B | | +73.37% | 12.39B | | -17.09% | 8.08B | | +2.81% | 5.86B | | +11.77% | 5.35B | | +29.65% | 4.63B | | -17.74% | 4.19B | | -35.26% | 2.44B | | +3.47% | 2.07B | | +4.85% | 1.88B |
Medical Equipment
|